Company Description
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.
The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
It offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper platform for bacterial and fungal identification and establish, DNA test strips, and; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions.
It provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment.
In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation.
The company was founded in 1960 and is headquartered in Billerica, Massachusetts.
| Country | United States |
| Founded | 1960 |
| IPO Date | Aug 4, 2000 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 11,396 |
| CEO | Frank Laukien |
Contact Details
Address: 40 Manning Road Billerica, Massachusetts 01821 United States | |
| Phone | 978 663 3660 |
| Website | bruker.com |
Stock Details
| Ticker Symbol | BRKR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001109354 |
| CUSIP Number | 116794108 |
| ISIN Number | US1167941087 |
| Employer ID | 04-3110160 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Burkhard Prause Ph.D. | President and Chief Executive Officer of Bruker Energy and Supercon Technologies, Inc. |
| Dr. Frank H. Laukien Ph.D. | Chairman, Chief Executive Officer and President |
| Gerald N. Herman CPA | Executive Vice President and Chief Financial Officer |
| Dr. Mark R. Munch Ph.D. | Corporate Executive Vice President and President of Bruker Nano Group and Corporate |
| Juergen Srega | President of Bruker CALID Group and Bruker Daltonics Division |
| Dr. Falko Busse Ph.D. | President of Bruker BioSpin Group |
| Thomas Bures | Chief Accounting Officer |
| J. Brent Alldredge J.D. | Senior Vice President, General Counsel, Secretary and Global Head of Compliance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 30, 2025 | SD | Form - SD |
| May 29, 2025 | 8-K | Current Report |
| May 19, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 14, 2025 | 8-K | Current Report |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| May 7, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| Apr 11, 2025 | ARS | Filing |
| Apr 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2025 | DEF 14A | Other definitive proxy statements |